Evidence supporting the use of: Boric acid
For the health condition: Thrush
Synopsis
Source of validity: Scientific
Rating (out of 5): 4
Boric acid is scientifically validated as a treatment option for vaginal thrush (vulvovaginal candidiasis), particularly in cases where standard antifungal therapies (such as azoles) have failed or when infection is caused by non-albicans Candida species. Numerous clinical studies and reviews, including those referenced by the Centers for Disease Control and Prevention (CDC) and the Infectious Diseases Society of America (IDSA), have shown boric acid (usually as 600 mg vaginal suppositories administered once daily for 14 days) to be safe and effective as a second-line or adjunctive therapy. Mechanistically, boric acid exerts antifungal and antiseptic effects, disrupting fungal cell walls and inhibiting the growth of Candida species. Its use is particularly recommended for recurrent or resistant yeast infections. However, boric acid should not be used orally or during pregnancy due to potential toxicity. The level of evidence is not the highest (i.e., not based on large randomized controlled trials), but the consistency of observational studies, case reports, and expert consensus supports a robust rating. In summary, boric acid is an evidence-based option for thrush when first-line treatments are ineffective, with guidelines from major medical organizations endorsing its use in specific situations.